Pharmaceuticals Search Engine [selected websites]

Loading

Thursday, May 24, 2012

PROLOR Biotech : Positive Results of Its Obesity/Diabetes Drug Candidate in Preclinical Weight Loss Study

PROLOR Biotech
April 17, 2012 - PROLOR Biotech, Inc. (NYSE Amex: PBTH) reported positive preclinical results from an animal study of its long-acting obesity/Type II diabetes drug candidate MOD-6030. The study was designed to measure the potential therapeutic effect of MOD-6030 injected once weekly as measured by weight loss, reduction in food intake, glycemic control and cholesterol levels. The study results will be presented at GTC's 5th Diabetes Drug Discovery and Development Conference on April 19, 2012 in Boston, MA.

In the study, MOD-6030 administered to diet-induced obese (DIO) mice once weekly over a 30-day period demonstrated significant efficacy in reducing weight, lowering blood glucose levels, increasing insulin sensitivity and reducing cholesterol levels as compared to a group that received placebo. Animals in the placebo group showed minimal changes in the study parameters, while the animals receiving MOD-6030 achieved on average a 28% reduction in weight, a 29% reduction in food intake, a 19% reduction in blood glucose levels and a 57% reduction in cholesterol levels. Body composition analysis showed that the weight loss resulted specifically from reductions in body fat... [PDF] PROLOR Biotech's Press Release -

Monday, May 7, 2012

LATITUDE Pharmaceuticals : Stable Liquid Glucagon Formulation

LATITUDE Pharmaceuticals
April 03, 2012 - LATITUDE Pharmaceuticals, Inc. (LPI) announced that its scientists have developed the first ever, ready-to-inject, stable liquid glucagon formulation (Nano-G). A glucagon formulation with these properties had been a highly sought after Holy Grail of drug developers for decades.

Currently, glucagon is indicated for emergency treatment of insulin-induced hypoglycemia and as a diagnostic aid for radiological examinations. Researchers have long been interested in evaluating glucagon for hypoglycemia prevention, the bi-hormonal insulin/glucagon pump and the treatment of obesity but have been thwarted by the absence of a stable injectable glucagon formulation.

Glucagon is a notoriously insoluble and unstable molecule and is therefore provided as a dried powder. Before use, the glucagon is dissolved in an acid solution by following a cumbersome, eight-step procedure that becomes an outsized task during life-threatening hypoglycemia.

Nano-G is a pH-neutral, isotonic, detergent-free, aqueous formulation that contains only FDA-approved injectable ingredients. Results from rigorous 6-month real-time and accelerated ICH stability testing predict a 2-yr shelf-life. Nano-G is also stable at body temperature, making it highly suitable for subcutaneous infusion pump delivery.

“Nano-G fulfills the long overdue need for a rapidly self-administered, auto-injector delivered glucagon for hypoglycemia rescue and is the missing piece needed for the bi-hormonal pump and novel combination therapies for obesity... LATITUDE Pharmaceuticals' Press Release -

Friday, April 13, 2012

AMA : Free ‘Weigh What Matters’ App to Help People Achieve Healthier Lifestyles

AMA Weigh What Matters app icon
Jan. 30, 2012 – Many Americans resolved to become healthier in the new year, but are having trouble monitoring their progress to achieve their goals. Now there's an app for that. The American Medical Association (AMA) released a free app today to help patients improve their overall health as part of the AMA Healthier Life Steps program, which promotes healthy choices and healthy lives.

"Every January, Americans implement New Year's resolutions that involve healthy eating and increased physical activity," said AMA President Peter W. Carmel, M.D. "This new app encourages people to work with their physicians to set healthy goals, and it allows users to track their progress and accomplish their goals."

AMA Weigh What Matters app screen

The Weigh What Matters app is free, easy to use and encourages users to consult with their physician to establish personal health goals for three categories: weight, eating and activity. Once goals are established, users can track their weight, physical activity and nutrition with daily entries. It also calculates a user's Body Mass Index (BMI) and provides a mechanism to view progress reports and email them to the user's physician.

"The AMA Healthier Life Steps program offers tools and information to help physicians and patients work together to promote longer, healthier lives," said Dr. Carmel. "Physicians and their staff can use this new app as a resource to work with patients to address challenging behavioral changes."...American Medical Association's Press Release -

Monday, March 26, 2012

Oragenics : Positive Clinical Results for its Proprietary Weight Loss Agent, LPT3-04

Oragenics
February 14, 2012 - Oragenics, Inc. (OTCBB:ORNI) announced that a recently completed randomized, double-blind, placebo-controlled, human clinical study with 32 enrolled subjects resulted in a statistically and clinically significant reduction in body weight when healthy, overweight and mildly obese adult volunteers were given daily supplementation of Oragenics’ Weight Loss Agent LPT3-04 over a twelve-week period. This study, sponsored by Oragenics, was conducted at the Miami Research Associates (MRA) clinical research facilities in Miami, Florida. MRA investigators also confirmed that there were no safety concerns with daily supplementation of LPT3-04 over the 12-week duration of the trial, and that no reports of serious adverse events, including depression, occurred during this trial. This human study result confirms the extensive results obtained from animal safety and efficacy studies completed to date by Oragenics, and suggests that LPT3-04, a natural occurring dietary substance with an excellent safety and tolerance profile, can support weight loss in overweight men and women.

The World Health Organization estimated that by 2015, there will be more than 1.5 billion overweight consumers. Further, according to a 2012 healthcare market research report published by Markets and Markets, the total global weight loss market is expected to be worth US$586.3 billion by 2014, with a compound annual growth rate of 10.9% from 2009 to 2014. These reports suggest that the opportunities for a scientifically-substantiated weight management product are impressive...[PDF] Oragenics' Press Release -

Friday, March 9, 2012

Hanmi : license agreement for a new anti-obesity botanical drug

Hanmi pharmaceuticals
16, Feb. 2012 - Hanmi pharmaceuticals announced that it has entered into a licensing agreement with AngioLab for a new anti-obesity botanical drug, ALS-L1023.

ALS-L1023 is a Melissa leaf (Lemon Balm) ethyl acetate dried extract, having excellent angiogenesis and MMP inhibitory activities. The inhibition of angiogenesis in the growing adipose tissue is a novel approach for the prevention and treatment of obesity having a high specificity to visceral fat (intra-abdominal fat).

AngioLab

A randomized, double-blind, placebo-controlled, phase II human trial was completed in ASAN Medical Center and Inje University Seoul Paik Hospital. The statistically significant reduction of visceral fat by 15% was observed in comparison with the baseline after 12 weeks. In safety assessment, there was no statistically significant Adverse Events. Furthermore, plasma adiponectin level has increased, while plasma free fatty acid level has decreased... Hanmi pharmaceuticals' Press Release -